China approves CanSino’s inhaled Covid-19 vaccine for emergency use
- The National Medical Products Administration has approved CanSino’s adenovirus-vectored Covid-19 vaccine for emergency use as a booster
- The watchdog has also okayed Livzon Pharmaceutical’s Covid-19 vaccine, one of just two new products against the disease cleared in more than a year
“The approval will have a positive impact on the company’s performance if the vaccine is subsequently purchased and used by relevant government agencies,” CanSino said.
The company cautioned, however, that it will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials.
China granted emergency use authorisation to Livzon Pharmaceutical Group’s Covid-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.
Cansino also said it was uncertain when its vaccine would be able to go to market, since additional administrative approvals are still needed, while sales would depend on the Covid-19 situation at home and abroad, as well as China’s vaccination rate.
Mainland China reported 1,848 new coronavirus cases for September 3, including both symptomatic and asymptomatic infections, compared with 1,988 new cases a day earlier.